Senti Biosciences Holdings, Inc. (SNTI) · Oct 13, 2026 · Acquisition
Vote adjourned — Meeting reconvened October 15 after no business was conducted
Senti Biosciences adjourned its annual meeting to solicit more votes for the Celadon-backed merger, pushing the decision to October 15.
Senti is a cash-constrained clinical-stage biotech trying to transfer substantially all of its existing business and lead SENTI-202 program to a Celadon-controlled private company, while leaving the public entity focused on its Regulator Dial platform and a smaller set of early-stage programs.
The merger vote did not fail, but it was not completed. Despite having a quorum, Senti adjourned the October 8 meeting specifically to seek additional support for the merger proposal. That is a modest negative signal versus the standing expectation that a scheduled shareholder vote would produce a result, because approval is still unresolved; however, the filing gives no vote tally and does not say the proposal is losing.
This changes timing more than substance. The merger, its proposed transfer of the pipeline, and the shareholder vote were already public, so the new information is mainly that Senti needs another week to secure approval—not a change to the transaction terms or the post-merger business plan. The proposals and record date remain unchanged.
Bottom line: The filing keeps the Celadon-backed merger alive but exposes execution uncertainty around shareholder approval. It matters as a delay and a mild warning sign, not as a rejection or a revised deal.
Revised annual meeting and merger vote, October 15
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!